Coherus Oncology, Inc. (CHRS)
NASDAQ: CHRS · Real-Time Price · USD
0.8525
-0.0459 (-5.11%)
Oct 30, 2026, 10:25 AM EDT - Market open
Coherus Oncology Stock Forecast
Stock Price Forecast
According to 6 analysts polled by S&P Global, Coherus Oncology stock has a consensus rating of "Buy" and an average price target of $7.75. The average 1-year stock price forecast is 809.09% higher than the current stock price, while the lowest is $4.00 (+369.21%) and the highest is $10 (+1,073.02%).
Price Target: $7.75 (+809.09%)
Analyst Consensus: Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Coherus Oncology stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Mar '26 | Apr '26 | May '26 | Jun '26 | Aug '26 | Oct '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 5 | 5 | 4 | 4 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 6 | 7 | 7 | 6 | 6 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| H.C. Wainwright | H.C. Wainwright | Buy Initiates $7 | Buy | Initiates | $7 | +721.11% | Oct 29, 2026 |
| Maxim Group | Maxim Group | Buy Maintains $4 | Buy | Maintains | $4 | +369.21% | Aug 7, 2026 |
| Guggenheim | Guggenheim | Buy Maintains $12 → $10 | Buy | Maintains | $12 → $10 | +1,073.02% | Aug 7, 2026 |
| Oppenheimer | Oppenheimer | Buy Maintains $10 | Buy | Maintains | $10 | +1,073.02% | Aug 6, 2026 |
| TD Cowen | TD Cowen | Buy Maintains n/a | Buy | Maintains | n/a | n/a | May 28, 2026 |
Financial Forecast
Revenue This Year
60.81M
from 42.17M
Increased by 44.19%
Revenue Next Year
100.37M
from 60.81M
Increased by 65.06%
EPS This Year
-0.86
from -1.36
EPS Next Year
-0.63
from -0.86
EPS and Forward PE are based on non-GAAP adjusted numbers.